Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
NCT04305054
What is this trial?
Generating plain-language summary...
Am I eligible?
Generating eligibility summary...
What's involved?
Summarizing study design...
Where and how to apply
Primary location
The Angeles Clinic and Research Institute ( Site 2009)